<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682121</url>
  </required_header>
  <id_info>
    <org_study_id>1002</org_study_id>
    <nct_id>NCT02682121</nct_id>
  </id_info>
  <brief_title>Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo</brief_title>
  <acronym>MAP-2</acronym>
  <official_title>Metabolic Alterations in Platelet Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) imposes an approximate 2-fold increased risk of atherothrombosis.&#xD;
      Patients with type 2 DM have a 2- to 4-fold increase in the risk of coronary artery disease&#xD;
      (CAD) and atherothrombotic complications. Current evidence indicates that altered platelet&#xD;
      function and &quot;reactivity&quot; are key determinants of arterial and venous thrombosis in metabolic&#xD;
      syndromes. In addition, venous thrombosis and pulmonary embolism are associated with&#xD;
      increased body mass index, a common feature of type 2 DM and the metabolic syndrome. Altered&#xD;
      platelet behavior, function, and phenotype may be critical factors in these thrombotic&#xD;
      complications as well. The mechanisms that lead to altered phenotype and function of&#xD;
      platelets in DM, and that underlie heightened contributions of platelets to thrombotic&#xD;
      complications in type 2 DM, are nevertheless incompletely understood. In this project, the&#xD;
      investigators will prospectively determine if clinical intervention with metformin--a&#xD;
      commonly-used therapeutic agent that reduces blood glucose, promotes weight loss, and&#xD;
      improves lipid profiles--reverses platelet reprogramming and hyperreactivity in obese&#xD;
      subjects with impaired fasting glucose and thus, at-risk for type 2 DM.&#xD;
&#xD;
      In addition to metformin, all participants will be given lifestyle modification (LSM)&#xD;
      education on diet and physical activity, followed by guidance on how to adhere to the LSM,&#xD;
      depending on random assignment to intervention group (education only (n=26) vs.&#xD;
      implementation intentions alone (n=27) vs. implementation intentions with partner (n=27)).&#xD;
      The LSM coaching for different intervention groups will allow the investigators to test&#xD;
      whether there are more effective ways for adherence than others. Participants in these three&#xD;
      LSM intervention groups will be further randomized to either Metformin (n=40) or Placebo&#xD;
      (n=40), such that participants in the three LSM groups will be randomly and evenly&#xD;
      distributed across the two study medication groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be gene expression levels of mitofusin 2 and uncoupling protein 2</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients on placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on Metformin, 850mg twice daily for 6mos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg twice daily</description>
    <arm_group_label>Active drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ageâ‰¥18 years&#xD;
&#xD;
          -  BMI&gt;25 kg/m2&#xD;
&#xD;
          -  fasting plasma glucose 100-125 mg/dL, AND/OR Hemoglobin-A1C between 5.5 and 6.4%,&#xD;
             AND/OR post-load glucose between 140 and 199 mg/dL on a 2-hour Oral Glucose Tolerance&#xD;
             Test (OGTT)&#xD;
&#xD;
          -  All inclusion criteria will be checked on participants' first in-person visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling to accept treatment assignment by randomization&#xD;
&#xD;
          -  participation in another clinical research trial&#xD;
&#xD;
          -  history of myocardial infarction or stroke&#xD;
&#xD;
          -  significant arrhythmia (e.g. atrial fibrillation)&#xD;
&#xD;
          -  active thromboembolic disease&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  serum creatinine levels greater than or equal to 1.5 mg/dL in males or greater than or&#xD;
             equal to 1.4 mg/dL in females&#xD;
&#xD;
          -  known hypersensitivity to metformin hydrochloride or any of its components&#xD;
&#xD;
          -  acute or chronic metabolic acidosis&#xD;
&#xD;
          -  inability to participate in lifestyle modifications&#xD;
&#xD;
          -  pregnancy; other glucose-lowering or diabetic therapy&#xD;
&#xD;
          -  systemic glucocorticoids&#xD;
&#xD;
          -  prescription weight loss medications&#xD;
&#xD;
          -  or otherwise deemed unsuitable by study investigators (e.g. unable to complete&#xD;
             follow-up visits, alcohol abuse, etc).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Weyrich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Matthew Rondina, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

